Insider Cluster (2 insiders) ·Filed Jul 8, 2026

RLAY

Relay Therapeutics, Inc.
NEUTRAL
Impact 2/10
Horizondays Processed2mo ago
Insider cluster: 2 insiders, $1.1M total
Actionable Insight • Neutral

Insider sales are immaterial in size and lack any bearish cross-filing context. No action warranted; monitor for any future cluster of larger sales or a material corporate event.

DirectionNeutral
Confidencehigh
Horizondays
Final — all horizons settled through T+60d
RLAY ▼ -8.05% at T+60d
NEUTRAL call ✗ call lost -8.05% · α vs SPY -10.36% · entry $19.63 → $18.05
Entry anchored
Jul 7, 03:59 PM ET
via exchange tick
T+1d
+5.71%
call +5.71% · α +4.86%
$20.75
settled 3mo ago
T+5d
-2.80%
call -2.80% · α -3.66%
$19.08
settled 3mo ago
T+20d
+0.31%
call +0.31% · α -2.97%
$19.69
settled 8w ago
T+60d
-8.05%
call -8.05% · α -10.36%
$18.05
settled 2d ago

Price Chart

Loading chart...

Executive Summary

Two insiders at Relay Therapeutics sold a combined $1.12M in stock over a one-week window, including a $955K sale by Peter Rahmer and a $162K sale by President of R&D Donald Bergstrom. The total sales represent approximately 0.03% of the company's $3.8B market cap, which is a trivial amount. Given the small size relative to market cap and the lack of any bearish cross-filing context (e.g., no earnings miss, no restructuring, no late filing), this cluster is routine and non-informative.

Key Financial Metrics

Direction
selling
Total Value
$1.1M
Insiders
2

Key Facts

  • Two insiders sold a total of $1.12M in RLAY stock from June 30 to July 6, 2026.
  • Peter Rahmer sold 50,000 shares at $19.09 for $955K.
  • Donald Bergstrom (President, R&D) sold 8,660 shares at $18.71 for $162K.
  • Total sales represent ~0.03% of RLAY's $3.8B market cap.
  • No recent earnings, restructuring, or other material corporate events in the cross-filing context.

Financial Impact

Insider sales of $1.12M are trivial relative to the $3.8B market cap (0.03%).

dilution

Risk Factors

  • Insider sales could increase if the stock appreciates further, but current levels are routine.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
94% bullish (18 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-RLAY-1783577187545
14 reports for RLAY
Performance horizon
73% Hit rate 8 of 11 directional calls best @ T+60▲ +65.12%May 19, 2026
Filters
Rows
Reports for RLAY — sortable, filterable
TypeNow
Sep 9, 2026
23d ago
Insider Cluster
NEUTRAL ★ 4/10
$18.66 $18.84▲ +0.96%▲ +1.62%$18.96 (+1.61%)
Aug 28, 2026
5w ago
Insider Cluster
BEARISH ★ 6/10
$18.77 $19.04▼ −1.44%▼ −1.33%$18.96 (−1.01%)
Aug 18, 2026
6w ago
Insider Cluster
BEARISH ★ 5/10
$20.61 $20.57▲ +0.19%▼ −0.01%$18.96 (+8.01%)
Jul 8, 2026
12w ago
Insider Cluster
NEUTRAL ★ 2/10
$19.63 $19.08▼ −2.80%▼ −3.66%$18.96 (−3.41%)
Jun 22, 2026
14w ago
144
NEUTRAL ★ 3/10
$17.44 $19.74▲ +13.19%▲ +12.18%$18.96 (+8.72%)
Jun 12, 2026
16w ago
Institutional Cluster
BULLISH ★ 6/10
$14.81 $15.88▲ +7.22%▲ +6.55%$18.96 (+28.02%)
May 21, 2026
19w ago
8-K
BEARISH ★ 6/10
$13.53 $14.26▼ −5.40%▼ −3.74%$18.96 (−40.13%)
May 21, 2026
19w ago
Press Release
BEARISH ★ 7/10
$13.66 $14.05▼ −2.86%▼ −1.01%$18.96 (−38.80%)
May 19, 2026
19w ago
424B5
BEARISH ★ 6/10
$13.02 $13.90▼ −6.76%▼ −4.96%$18.96 (−45.62%)
May 19, 2026
19w ago
Press Release
BEARISH ★ 7/10
$13.02 $14.43▼ −10.83%▼ −9.59%$18.96 (−45.62%)
Showing 10 of 14

US Market Status

Market Closed — Opens Mon (37h 48m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published Jul 9, 2026